CHCWM – Cancer & Hematology Centers of West Michigan

INBRX-109 (InhibRx)

Description:  An Open Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Mechanism of Action:  IgG1 antibody that targets the human TRAIL death receptor (DR5)

Target Patient Population:  Expansion cohorts for chondrosarcoma and Ewings sarcoma; in combination with FOLFIRI for pancreatic cancer

Study Design:  Drug is given IV every 3 weeks.